CXCR4 and neoplasm: Investigating a potential interaction of CXCR4/CXCL12 axis with the AR, the most common therapeutic target for systemic therapies, IHC revealed AR expression in EC more affecting tumor areas compared to stromal tissue (Fig. S4).